Omnia Family Wealth LLC Grows Stake in Akari Therapeutics, Plc (NASDAQ:AKTX)

Omnia Family Wealth LLC raised its stake in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the 4th quarter, HoldingsChannel reports. The firm owned 87,628 shares of the biopharmaceutical company’s stock after acquiring an additional 28,511 shares during the quarter. Omnia Family Wealth LLC’s holdings in Akari Therapeutics were worth $273,000 as of its most recent SEC filing.

Akari Therapeutics Price Performance

Shares of Akari Therapeutics stock remained flat at $1.19 on Friday. 10,002 shares of the stock traded hands, compared to its average volume of 16,491. The stock’s 50-day moving average is $1.77 and its 200-day moving average is $2.59. Akari Therapeutics, Plc has a fifty-two week low of $1.08 and a fifty-two week high of $5.50.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Akari Therapeutics in a report on Wednesday. They set a “sell” rating on the stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.